ICLUSIG Drug Patent Profile

Which patents cover Iclusig, and when can generic versions of Iclusig launch?

Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and nine patent family members in twenty-four countries.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ponatinib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Iclusig

Iclusig was eligible for patent challenges on December 14, 2016.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (ponatinib hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ICLUSIG

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ICLUSIG

Paragraph IV (Patent) Challenges for ICLUSIG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ICLUSIG	Tablets	ponatinib hydrochloride	10 mg and 30 mg	203469	1	2022-12-12
ICLUSIG	Tablets	ponatinib hydrochloride	15 mg and 45 mg	203469	1	2021-03-31

US Patents and Regulatory Information for ICLUSIG

ICLUSIG is protected by seventeen US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No	9,493,470		Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No	11,192,897			Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-002	Dec 14, 2012		RX	Yes	No	9,493,470		Y	Y

International Patents for ICLUSIG

When does loss-of-exclusivity occur for ICLUSIG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Chile

China

Hong Kong

Japan

Mexico

New Zealand

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ICLUSIG around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5273038
Japan	5790629
Mexico	2021002255

Supplementary Protection Certificates for ICLUSIG

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1973545	C01973545/01	Switzerland		FUSION; FORMER OWNER: ARIAD PHARMACEUTICALS, INC., US
1973545	490	Finland
1973545	C300631	Netherlands		PRODUCT NAME: PONATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701

ICLUSIG Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What is the current market position of ICLUSIG?

ICLUSIG (ponatinib) is a kinase inhibitor marketed by Takeda Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Approved by the FDA in 2012, it addresses resistant or intolerant cases of these hematologic malignancies, especially those with the T315I mutation.

As of 2023, ICLUSIG's global sales approximate $600 million, with the majority generated in the United States. Sales growth has been steady, driven by expanded indications and increased physician awareness of its efficacy in resistant cases. Patent protection extends through at least 2028, with potential for extension based on additional approvals or formulations.

What are the key product characteristics and regulatory aspects?

Efficacy Profile

ICLUSIG demonstrates rapid and durable responses in resistant CML and Ph+ ALL. It inhibits BCR-ABL kinase activity, including T315I mutants, one of the most resistant forms.

Safety Profile

Adverse events include arterial occlusive events, cardiac events, hypertension, and hepatotoxicity. FDA black-box warnings are in place, affecting prescribing patterns.

Regulatory Status

• FDA approval: 2012 for Ph+ ALL and resistant/de novo CML.
• Additional approvals: Japan (2014), European Union (2017) with label variations.
• Indication breadth: Approved for use after at least two prior TKIs or in presence of T315I mutation.

Patent and Market Exclusivity

Patents expiring in 2028, with orphan drug status in the US providing potential exclusivity extensions.

What are the competitive dynamics?

ICLUSIG faces competition from drugs such as:

• Dasatinib and Nilotinib, first- and second-generation TKIs with broader indications.
• Asciminib (Takeda's allosteric inhibitor), with a different mechanism of action and FDA approval in 2021 for resistant CML, positioning as a potential competitor.
• Generic TKIs beginning to enter markets as patents expire.

The differentiation is based on efficacy in resistant cases and T315I mutation activity, limiting the competitive impact in specific niches.

What are the growth drivers and risks?

Growth Drivers

• Increasing prevalence of resistant CML (~100,000 patients globally).
• Expanded use in earlier lines of therapy following clinical data.
• Geographic expansion into emerging markets.

Risks

• Safety concerns could limit prescribing and affect sales.
• Competition from newer agents, especially Asciminib.
• Regulatory risks, including potential label restrictions or black-box warnings.
• Market entry of generics post-patent expiry.

What is the investment outlook based on fundamentals?

ICLUSIG’s revenue stability depends on its niche of resistant disease and mutation coverage. The sales are unlikely to grow significantly without indication expansion or label improvements. R&D investments by Takeda aim to develop next-generation kinase inhibitors, which could either cannibalize ICLUSIG’s market or extend Takeda’s leadership in resistant CML treatments.

Profit margins remain high due to the drug’s specialized market, but patent expiration in 2028 poses long-term revenue risks. Divestment, licensing, or portfolio repositioning could impact valuation.

Financial summary table

Metric	2022 Estimate	Notes
Global sales	$600 million	Steady growth since 2012
Operating margin	50%	Reflecting high specialization and pricing power
R&D expenditure	$150 million	Focused on next-generation therapies
Patent expiry	2028	Potential for generic competition post-expiry

Key considerations for investors

• Maintain a positive outlook if resistant CML cases grow.
• Monitor regulatory developments and label updates.
• Watch for Asciminib’s market penetration.
• Assess Takeda’s R&D pipeline for future growth opportunities.
• Consider the impact of patent expiration on revenue streams.

Key Takeaways

ICLUSIG remains a niche but important drug in resistant CML, with stable sales and high margins. Its growth relies on market expansion and indication scope, constrained by safety concerns and competition. Post-2028, revenue streams face potential erosion unless new formulations or indications are approved.

FAQs

1. Is ICLUSIG expected to be replaced by newer therapies?

   • Its niche role in resistant cases likely sustains demand, but competition from drugs like Asciminib could diminish its market share.

2. What is the likelihood of patent extensions?

   • Patent expiry is set for 2028, with potential for extensions based on regulatory and formulation changes.

3. Are there ongoing clinical trials for ICLUSIG?

   • Yes, Takeda is exploring combination therapies and new formulations to improve efficacy and safety profiles.

4. What are the main safety concerns?

   • Arterial occlusive events and cardiovascular issues are significant, influencing prescribing decisions.

5. How does ICLUSIG compare with competitors?

   • It offers unique activity against T315I mutations but faces competition from multiple TKIs and emerging agents like Asciminib, which have broader indications or different mechanisms.

---

References

1. Takeda Pharmaceuticals. (2022). ICLUSIG (ponatinib) Prescribing Information.
2. FDA. (2012). ICLUSIG (ponatinib) approval announcement.
3. European Medicines Agency. (2017). ICLUSIG marketing authorization.
4. ClinicalTrials.gov. (2023). Takeda-sponsored studies on ponatinib.
5. IQVIA. (2023). Oncology drug market data.